Артериальная гипертензия

Расширенный поиск

Органопротективные свойства фиксированной комбинации верапамила СР и трандолаприла

Полный текст:

Об авторах

Ж. Д. Кобалава
Российский университет дружбы народов, ГКБ № 64, г. Москва

Ю. В. Котовская
Российский университет дружбы народов, ГКБ № 64, г. Москва

А. А. Рубанова
Российский университет дружбы народов, ГКБ № 64, г. Москва

Список литературы

1. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). Кардиваскулярная терапия и профилактика, приложение. 2004;с.20.


3. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.


5. Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.


7. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-1992.


9. JNC 6. National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157:2413-2446.


11. Holzgreve H.. Safety profile of the combination of verapamil and trandolapril.Journal of Hypertension 1997, 15 (suppl 2): S51-S53.


13. Viskoper R. J., Compagnone D., Dies R., Zilles P.. Verapamil and Tradolapril Alone in Fixed Combination on 24-hour Ambulatory Blood Pressure Profiles of Patients with Moderate Essential Hypertension. Curr Ther Res 1998;58 (6):342-351


15. Messerli F., Frishman W.H., Elliott W. J., for the Trandorapril Study Group. Effects of Verapamil and Trandolapril in the Treatment of Hypertansion. Am J Hypertens1998;11:322-327


17. Messerli F., Frishman W. H., Elliot W.J., Bacher P.H., Pepine C.J.. Antihypertensive Properties of a High-Dose Combination of Trandolapril and Verapamil-СР. Blood Pressure 2006:1-4


19. INVEST (International Verapamil SR /Trandolapril Study) JAMA 2003;290:2805-2816


21. The Danish Study Group on Verapamil in Myocardial Infarction. The effect of Verapamil on mortality and major events after myocardial infarction. The Danish Verapamil infarction Trial (DAVIT) IL Am J Cardiol 1990; 66: 779-785


23. The Danish Study Group on Verapamil in Myocardial Infarction. Secondary prevention with verapamil after myocardial infarction. Am J Cardial 1990: 66: 331-401


25. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction wiyyh clinical evidence of heart failure/ Lancert 1993: 342: 821-828


27. Kober L, Torp-Pedersen C, Carlsen J, Bagger H, Eliasen P, Lyngborg R, Videbak J, Cole D, Auclert Iet all . A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after acute myocardial infarction. N Engl J Med 1995; 333:1670-1676


29. Ambrosioni E, Borghi C, Magnani B, for the SMILE Study Investigators. The effect of angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332-:80-85


31. Moye LA, Pfeffer MA, Wun CC, Davis BR et all for the SAVE Investigators. Uniformity of captopril benefit in the SAVE study: subgroup analysis. Eur Haert J 1994; 15(suppl B);2-8


33. Kornowski R, Goldbourt U, Zion M et all for the SPRINT Study Group. Predictors and long-term prognostie significance of recurrent infarction in the year after a first myocardial infarction. Am J Cardial 1993; 72:883-888


35. Hansen J. F., Hagerup L., Sigurd B., MD at all for the Danish Verapamil Infarction Trial (DAVIT) Study Group. Cardiac Event Rates After Acute Myocardial Infarction in Patients Treated With Verapamil and Trandolapril Versus Trandolapril Alone.Am J Cardiol, 1997; 79: 738-741.


37. Eurich DT, Majumdar СР, Tsuyuki RT, Johnson JA. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 2004;27:1330-1334.


39. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-1650


41. Kloke H.J., Branten A.J., Huysmans F.T., Wetzals J.F. Antihyepertensive treatmnt of patients with proteinuric renal diesease: risks or benefits of calcium channel blockers. Kidney Intern 1998;53:1559-1573


43. Estacio RO, Gifford N, Jeffers BW, Schrier RW. Effect of blood pressure cntrol on diabetic micrivascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23:B54- B64


45. The PROCOPA Study Group. Dissociation Between Blood Pressure Reduction and Fall in Proteinuria in Primary renal Disease: a Randomized Double-Blind Trial. Journal of Hypertension 2002, 20:729-731.


47. Bakris G. L., Weir M.R., DeQuattro V., McMahon F. G.. Effects of ACE Inhibitor/Calcium Antagonist Combination on Proteinuria in Diabetic Nephropathy. Kidney International1998;54:1283-1289.


49. Rubio-Guerra A. F., Trevino-Gomezharper C., Rodriguez-lopez L. at al. Renoprotective Effects of the Combination Trandolapril/Verapamil in Patients with Type 2 Diabetes Mellitus and Hypertension. Clin Drug Invest, 2002; 22 (8), 541-546.


51. Rubio-Guerra A. F., Trevino-Gomezharper C., Rodriguez-lopez L. at al. The Effect of Trandolapril and Its Fixed-Dose Combination With Verapamil on Proteinuria in Normotensive Adults With Type 2 Diabetes. Diabetes Сare 2004;27:1688-1691


53. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.


55. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet.1998;351:1755-62.


57. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.


59. Schneider M., Lerch M., Papiri M. at al. Metabolic Neutrality of Combined Verapamil-Trandolapril Treatment in Contrast to Beta-Blocker-low-Dose Chlortalidone Treatment in Hypertensive Type 2 Diabetes. Journal of Hypertension, 1996, 14: 669-677.


61. Fernandez R., Puig J.G., Rodrigez-perez J.C. at al on Behalf of the TRAVEND Study Group. Effect of Two Antihypertensive Combinations on metabolic Control in Type-2 Diabetic hypertensive patients With Albuminuria: a Randomised, Double-Blind Study. Journal of Human Hypertension. 2001; 15: 849-856.


63. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145-1151.


65. Ritz E. Albuminuria and vascular damage - the vicious twins. N Engl J Med 2003;348:2349-2352


67. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes melllitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259


69. Ruggenenti P., Fassi A., Bruno S. Preventing Microalbuminuria in Type 2 Diabetes. NEJM 2004;351 (19):1941-1951.


Для цитирования:

Кобалава Ж.Д., Котовская Ю.В., Рубанова А.А. Органопротективные свойства фиксированной комбинации верапамила СР и трандолаприла. Артериальная гипертензия. 2007;13(4):266-274.

For citation:

Kobalava Z.D., Kotovskaya Yu.V., Rubanova A.A. Organoprotective properties of fixed-drug combination verapamil-SR and trandolapril. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2007;13(4):266-274. (In Russ.)

Просмотров: 157

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)